journal article·2020-12-01

Protein Stabilization and Delivery: A Case Study of Invasion Plasmid Antigen D Adsorbed on Porous Silica

Nicole A. Montoya, Kaylee E. Barr, Simon Velasquez Morales, Jorge E. Umana, Channary Ny, Rhianna E. Roth, Edward J. Reyes, Brian C. Kirchhoff, Eric R. Hartman, Lillian L. Higgins, Kalena M. Nichol, Ana Rita C. Morais, Alan M. Allgeier, Phillip Gao, William D. Picking, David R. Corbin, Mark B. Shiflett

Langmuir· Volume 36· Issue 47
Publisher page

Abstract

Approximately half of all vaccines produced annually are wasted because effectivity is dependent on protein structure and heat exposure disrupts the intermolecular interactions needed to maintain the structure. Thus, most vaccines require a temperature-controlled supply chain to minimize waste. A more sustainable technology was developed via the adsorption of invasion plasmid antigen D (IpaD) onto mesoporous silica, improving the thermal stability of this protein-based therapeutic. Seven silicas were characterized to determine the effects of pore diameter, pore volume, and surface area on protein adsorption. The silica–IpaD complex was then heated above the IpaD denaturing temperature and N, N -dimethyldodecylamine N -oxide was used to remove IpaD from the silica. Circular dichroism confirmed that the adsorbed IpaD after the heat treatment maintained a native secondary structure rich in α-helix content. In contrast, the unprotected IpaD after heat treatment lost its secondary structure. Isotherms using Langmuir, Freundlich, and Temkin models demonstrated that the adsorption of IpaD onto silicas is best fit by the Langmuir model. If pores are less than 15 nm, adsorption is negligible. If the pores are between 15 and 25 nm, then monolayer coverage is achieved and IpaD is protected from thermal denaturing. If pores are larger than 25 nm, the adsorption is a multilayer coverage and it is easier to remove the protein from the silica because of a less-developed hydrogen bond network. This case study provides strong evidence that IpaD is thermally stabilized via adsorption on mesoporous silica with the proper range of pore sizes.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advanced Drug Delivery Systems · Protein purification and stability · Bacteriophages and microbial interactions

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Institute for Sustainable Engineering, Department of Chemical and Petroleum Engineering, University of Kansas, 1530 W. 15th Street, Lawrence, Kansas 66045, United States

Center for Environmentally Beneficial Catalysis, University of Kansas, 1501 Wakarusa Dr, Lawrence, Kansas 66047, United States

Shankel Structural Biology Center, University of Kansas, 2034 Becker Drive, Lawrence, Kansas 66047, United States

Department of Pharmaceutical Chemistry, University of Kansas, 2093 Constant Avenue, Lawrence, Kansas 66047, United States

Funding

University of Kansas

References (41)

Show source-provided references
1. 10.1016/j.vaccine.2016.08.04510.1016/j.vaccine.2016.08.045 ↗
2. WHO EPI Logistics. https://www.who.int/countries/eth/areas/immunization/epi_logistics/en/index1.html (accessed in 2020).
3. WHO/UNICEF. Achieving immunization targets with the comprehensive effective vaccine management (EVM) framework. https://apps.who.int/iris/bitstream/handle/10665/254717/WHO-IVB-16.09-eng.pdf;jsessionid=01B2497AA0D9C8C610F9F68A27BA4BD0?sequence=1 (accessed in 2020).
4. 10.1016/j.vaccine.2016.12.07210.1016/j.vaccine.2016.12.072 ↗
5. 10.1016/j.vaccine.2015.05.07110.1016/j.vaccine.2015.05.071 ↗
6. 10.1016/j.vaccine.2016.11.09710.1016/j.vaccine.2016.11.097 ↗
7. 10.2174/138527281966615060121134910.2174/1385272819666150601211349 ↗
8. 10.1038/srep4656810.1038/srep46568 ↗
9. 10.1021/nn301866q10.1021/nn301866q ↗
10. 10.1002/adma.20110476310.1002/adma.201104763 ↗
11. 10.1021/nn506327610.1021/nn5063276 ↗
12. 10.1016/j.vaccine.2020.02.00510.1016/j.vaccine.2020.02.005 ↗
13. 10.1039/c3nr00357d10.1039/c3nr00357d ↗
14. 10.1016/j.ijpharm.2014.01.03710.1016/j.ijpharm.2014.01.037 ↗
15. 10.1038/s41598-019-47657-910.1038/s41598-019-47657-9 ↗
16. 10.1128/iai.00440-0610.1128/iai.00440-06 ↗
17. Kotloff K. · Bull. W. H. O. · 1999 · 77 · 651
18. 10.1093/infdis/159.6.112610.1093/infdis/159.6.1126 ↗
19. Zhang L. · 2009
20. 10.1021/bi060625v10.1021/bi060625v ↗
21. 10.1128/iai.00190-0910.1128/iai.00190-09 ↗
22. 10.1128/iai.06174-1110.1128/iai.06174-11 ↗
23. 10.1016/0264-410x(94)00011-b10.1016/0264-410x(94)00011-b ↗
24. 10.1016/j.vaccine.2009.11.00110.1016/j.vaccine.2009.11.001 ↗
25. 10.1128/iai.64.10.4074-4077.199610.1128/iai.64.10.4074-4077.1996 ↗
26. 10.1128/iai.72.2.923-930.200410.1128/iai.72.2.923-930.2004 ↗
27. 10.1128/jcm.31.2.454-457.199310.1128/jcm.31.2.454-457.1993 ↗
28. 10.4049/jimmunol.164.4.222110.4049/jimmunol.164.4.2221 ↗
29. Gasteiger E. · 2005
30. 10.1074/jbc.M60794520010.1074/jbc.M607945200 ↗
31. 10.1006/bbrc.1995.238010.1006/bbrc.1995.2380 ↗
32. Webb P. A. · 1997
33. 10.1021/la201938u10.1021/la201938u ↗
34. Rawlings J. B. · 2012
35. 10.1021/cr200117810.1021/cr2001178 ↗
36. 10.3390/molecules2205085710.3390/molecules22050857 ↗
37. 10.1016/j.theochem.2006.12.04310.1016/j.theochem.2006.12.043 ↗
38. 10.1016/s1389-1723(01)80127-410.1016/s1389-1723(01)80127-4 ↗
39. 10.1021/la000273810.1021/la0002738 ↗
40. 10.1021/la049720010.1021/la0497200 ↗
41. 10.1006/jcis.1995.143110.1006/jcis.1995.1431 ↗